Telescope Innovations (OTCQB: TELIF) Charts Course for Growth with Strong Revenue Surge and Strategic Partnerships
Telescope Innovations Corp. has unveiled its fiscal year 2025 results, showcasing a significant 31.8% year-over-year revenue increase to CAD $5.8 million. This top-line growth, however, was accompanied by a widening Adjusted EBITDA loss of CAD $402,000, up from $152,000 in the prior fiscal year, as the company continued to reinvest heavily in research and development and commercialization efforts. Total expenses climbed to CAD $7.3 million for the period ending August 31, 2025.
The company highlighted several key operational milestones that underscore its strategic direction in intelligent automation and advanced chemical manufacturing. A multi-year, funded Self-Driving Lab (SDL) project with pharmaceutical giant Pfizer is progressing, signaling a strong validation of Telescope’s proprietary technology in a highly demanding sector. This collaboration is a critical step in demonstrating the scalability and efficacy of SDLs for drug discovery and development.
In parallel, Telescope is aggressively expanding its commercial reach. The company reported record quarterly sales for its DirectInject-LC product line, coupled with successful market entries in Europe and Asia. This geographic expansion is a testament to the growing global demand for automated and efficient chemical processing solutions.
Furthermore, Telescope has made significant strides in the burgeoning battery materials sector. The company announced the successful production and initial sample shipments of battery-grade lithium sulfide. Utilizing a proprietary low-temperature manufacturing method, Telescope aims to address the critical need for high-purity materials essential for next-generation battery technologies. This move positions Telescope to capitalize on the accelerating transition to electric vehicles and renewable energy storage.
Looking ahead, Telescope plans to deploy its first Self-Driving Lab for pharmaceutical development in Korea during fiscal year 2026, further cementing its international presence and capabilities.
“These results reflect the growing validation of Telescope’s technology across multiple end markets,” stated Henry Dubina, CEO of Telescope Innovations. “From continued progress on our SDL program with Pfizer to record DirectInject-LC sales and the delivery of battery-grade lithium sulfide, FY 2025 marked an important transition from development to commercialization. We’re excited to be addressing growing demand for intelligent, automated chemistry and the resulting manufacturing insights it provides.”
Telescope Innovations is focused on developing scalable manufacturing processes and tools for the pharmaceutical and chemical industries. By integrating flexible robotic platforms with advanced artificial intelligence software, the company enhances experimental throughput, efficiency, and data quality, aiming to provide modern chemical technology solutions to address critical challenges in health and sustainability.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/14933.html
